Unraveling the Molecular Mechanisms of Neurodegenerative Diseases: A Biomedical Review

Leonn Srinagesh^*
*Correspondence: Leonn Srinagesh, Department of Health and Biomedical Sciences, University of Texas Rio Grande Valley, Brownsville, USA, Email:

Keywords

Biomedical science • Immunology • Precision medicine

Introduction

Nanomedicine is a cutting-edge interdisciplinary field that harnesses the unique properties of nanomaterials to revolutionize healthcare. By manipulating materials at the nanoscale level, nanomedicine offers innovative solutions for diagnosing, treating, and preventing various diseases. Nanoparticles, nanoscale drug delivery systems, and nanosensors are just a few examples of the transformative applications of nanotechnology in medicine. This article explores the exciting potential of nanomedicine and its role in addressing health challenges and improving patient outcomes. Neurodegenerative diseases are a group of debilitating disorders characterized by the progressive degeneration of nerve cells (neurons) in the central nervous system. These diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS), result in a gradual decline in cognitive, motor, and sensory functions. Despite extensive research, the precise molecular mechanisms underlying these diseases remain complex and multifaceted. This article delves into the current understanding of the molecular mechanisms involved in neurodegenerative diseases from a biomedical perspective [1].

Literature Review

Biotechnology has revolutionized drug discovery by enabling the identification and characterization of therapeutic targets with unprecedented precision. Tools like high-throughput screening and computational biology have accelerated the process of identifying potential drug candidates, thereby expediting the early stages of drug development. Recombinant DNA technology lies at the core of biotechnology-driven drug development. The ability to clone, modify, and express genes in heterologous systems has led to the production of therapeutic proteins and peptides, including insulin, growth factors, and monoclonal antibodies. These biopharmaceuticals have become cornerstones of modern medicine, offering targeted therapies with reduced side effects. Monoclonal antibodies have emerged as a powerful class of therapeutics, capable of targeting specific antigens and modulating the immune response. Biotechnology-driven advancements in immuno-oncology have revolutionized cancer treatment, providing new avenues for immunotherapies and personalized medicine approaches [2,3].

Discussion

Gene therapy represents a ground breaking area in drug development, with the potential to cure genetic diseases by introducing functional genes or modifying existing ones. The advent of genome editing technologies, such as CRISPR/ Cas9, has further expanded the possibilities of precise gene manipulation, offering potential cures for a wide range of inherited disorders. Despite the remarkable progress, biotechnology-driven drug development faces challenges related to regulatory approvals, manufacturing complexities, and high costs [4]. The intricate nature of biopharmaceuticals necessitates stringent quality control and safety assessments, which pose unique challenges compared to traditional small-molecule drugs. The future of drug development lies in harnessing the full potential of biotechnology, further exploring multi-omics approaches, and integrating AI-driven technologies to accelerate drug discovery and development. Biotechnology-driven drug therapies hold immense promise for addressing unmet medical needs, delivering precise treatments, and transforming the landscape of healthcare. In response to injury and protein aggregates, the brain's immune cells, including microglia and astrocytes, become activated, leading to a state of chronic neuroinflammation. While inflammation is a protective mechanism, sustained activation of immune cells can release pro-inflammatory cytokines and reactive molecules that contribute to neuronal damage. Neurons are particularly susceptible to oxidative stress due to their high metabolic activity and limited regenerative capacity. Oxidative stress occurs when the balance between Reactive Oxygen Species (ROS) and antioxidant defenses is disrupted. The accumulation of ROS damages cellular components, including lipids, proteins, and DNA. This oxidative damage contributes to neuroinflammation and neuronal death observed in neurodegenerative diseases [5,6].

Conclusion

Biotechnology has ushered in a new era of drug development, seamlessly integrating science and technology to redefine medicine's frontiers. From biopharmaceuticals and gene therapies to personalized medicine approaches, biotechnology-driven drug development continues to forge ahead, shaping the future of healthcare. As we embrace the transformative power of biotechnology, we move closer to a new era of medicine, where targeted, precise, and patientcentric therapies offer hope and healing to patients worldwide. In conclusion, neurodegenerative diseases are complex and multifaceted disorders that arise from the interplay of various molecular mechanisms. Protein misfolding, oxidative stress, mitochondrial dysfunction, neuroinflammation, excitotoxicity, genetic factors, impaired autophagy, epigenetic modifications, and blood-brain barrier dysfunction collectively contribute to the progression of these diseases. A comprehensive understanding of these molecular mechanisms is crucial for developing effective therapeutic strategies aimed at slowing down or halting the progression of neurodegenerative diseases and improving the quality of life for affected individuals.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Batool, Shadab, Hussain Raza, Jawwad Zaidi and Saba Riaz, et al. "Synapse formation: From cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders." J Neurophysiol (2019).

Google Scholar, Crossref, Indexed at

2. S Stem, Maxwell and Thomas W Gardner. "Neurodegeneration in the pathogenesis of diabetic retinopathy: Molecular mechanisms and therapeutic implications." Curr Med Chem 20 (2013): 3241-3250.

Google Scholar, Crossref, Indexed at

3. Wu, Shi-Bei and Yau-Huei Wei. "AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: Implication of the cell survival in mitochondrial diseases." Biochim Biophys Acta Mol Basis D 1822 (2012): 233-247.

Google Scholar, Crossref,  Indexed at

4. Myszczynska, Monika A., Poojitha N. Ojamies, Alix MB Lacoste and Daniel Neil, et al. "Applications of machine learning to diagnosis and treatment of neurodegenerative diseases." Nat Rev Neurol 16 (2020): 440-456.

Google Scholar, Crossref,  Indexed at

5. Babic Leko, Mirjana, Vera Župunski, Jason Kirincich and Dinko Smilovic, et al. "Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion." Behav Neurol 2019 (2019).

Google Scholar, Crossref,  Indexed at

6. Hannan, Md Abdul, Raju Dash, Abdullah Al Mamun Sohag and Il Soo Moon. "Deciphering molecular mechanism of the neuropharmacological action of fucosterol through integrated system pharmacology and in silico analysis." Mar Drugs 17 (2019).

Google Scholar, Crossref,  Indexed at